Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors

NCT02013336 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

30

Enrollment

NETWORK

Sponsor class

Conditions

Recurrent or Refractory Solid Tumors
Ewing Sarcoma
Rhabdomyosarcoma
Neuroblastoma
Osteosarcoma

Interventions

DRUG: MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide

Sponsor

South Plains Oncology Consortium